Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation
Jianxing Lai, Duoduo Zhao, Xuwen Wang, Binben Wang, Jinliang Nan · 2026
Read Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation by Jianxing Lai, Duoduo Zhao, Xuwen Wang, Binben Wang, Jinliang Nan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619473.txt.
Description
Jianxing Lai, Duoduo Zhao, Xuwen Wang, Binben Wang, and Jinliang Nan look for new uses for approved drugs in allergic asthma, in a 2026 study. They focus on a protein called Pendrin, which is more active in the airway lining of people with asthma and is tied to mucus build-up. Data from single cells pointed to Pendrin as a strong target worth testing.
Using the known shape of the protein, they screened approved drugs that might fit its blocking pocket. Six drugs slowed the protein in lab tests, and two worked better than the standard blocker used for comparison. The effect was partial and needed high doses, so the authors treat the result as an early lead, not proof of a cure.
Catalog record
| CREATOR | Jianxing Lai, Duoduo Zhao, Xuwen Wang, Binben Wang, Jinliang Nan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |